Will liquid biopsies become our fluid transition to personalized immunotherapy?

Non-small-cell lung cancer (NSCLC) treatment has moved away from the 'same-for-all-therapy' standstill of the previous decades towards personalized therapy strategies. Improvements in molecular diagnostics have gradually increased our understanding of the genetic make-up of tumours, indeed allowing more targeted therapy. This has been the case for just over a decade now, initiated by the identification of activating EGFR driver mutations in tumours with dramatic responses to gefitinib [1, 2].